Zentalis Pharmaceuticals (ZNTL) Asset Utilization Ratio (2024 - 2025)
Zentalis Pharmaceuticals' quarterly Asset Utilization Ratio came in at 0.08 in Q3 2025, down 8.07% year-on-year from 0.09 in Q3 2024, and up 8.36% quarter-over-quarter from 0.07 in Q2 2025.
Zentalis Pharmaceuticals has reported Asset Utilization Ratio for 2 years, with the latest figure at 0.08 in Q3 2025.
- For the quarter ending Q3 2025, Asset Utilization Ratio fell 8.07% year-over-year to 0.08; the trailing twelve-month figure through Sep 2025 stood at 0.08 (down 8.07% YoY), and the FY2024 full-year result was 0.14, changed N/A from the prior year.
- Asset Utilization Ratio for Q3 2025 stood at 0.08, up from 0.07 in the prior quarter.
- The five-year high for Asset Utilization Ratio was 0.15 in Q4 2024, with the low at 0.07 in Q1 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Zentalis Pharmaceuticals | 280.35 Mn | 280.35 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.07 |
| Mar 31, 2025 | 0.07 |
| Dec 31, 2024 | 0.15 |
| Sep 30, 2024 | 0.09 |
| Jun 30, 2024 | 0.08 |
| Mar 31, 2024 | 0.07 |